摘要:
The present invention provides modulators of β-catenin phosphorylation. More specifically, the present invention provides inhibitors and enhancers of β-catenin Serine 45 (S45) phosphorylation. Examples of inhibitors provided by the invention are the proteins Dishevelled (Dvl), Wnt, phosphatase PP2A and CKI7. Examples of enhancers of beta-catenin phosphorylation are phosphatase inhibitors and proteins that promote β-catenin acetylation, like FRAT1. In addition, the present invention provides compositions and uses of the modulators of the invention, specifically for the treatment of cancer, as well as a method for screening such modulators.
摘要:
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
摘要:
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
摘要:
Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
摘要:
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
摘要:
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
摘要:
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
摘要:
Compositions and methods for modulating the activation of nuclear factor .kappa.B (NF-.kappa.B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I.kappa.B.alpha. and/or I.kappa.B.beta.. Such compositions may be used for treating diseases associated with NF-.kappa.B activation. Modulating agents include peptides that comprise a recognition domain for E3 ubiquitin ligase.